Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Table 1 Baseline characteristics of all patients versus non-HSCT eligible patients only in the LYM-3002 trial

Variable	All patients (n = 487)	Clinically ineligible for HSCT only (n = 407)
Age at baseline	64.29	65.82
Female	26.1 %	26.8 %
European Union	27.9 %	31.2 %
North America	2.9 %	6.3 %
Rest of the World	69.2 %	65.6 %
Stage II	6 %	6 %
Stage III	20 %	22 %
Stage IV	74 %	72 %
ECOG 0	40 %	43 %
ECOG 1	47 %	47 %
ECOG 2	13 %	10 %
Mean patient weight (kg)	70.59	70.03
Body surface area (m²)	1.80	1.79

Abbreviations: ECOG Eastern Cooperative Oncology Group, HSCT haematopoietic stem cell transplantation

ISSN: 1471-2407